

PUBLICATIONS
Mark Duncan Schleinitz, MD, MS

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Wang, G.F., Nikovits, W., Schleinitz, M. and Stockdale, F.E. Atrial chamber specific expression of the slow myosin heavy chain 3 gene in the embryonic heart. 1996. *J Biol Chem.* 271(33):19,836-45.
2. Wang, G.F., Nikovits, W.Jr., Schleinitz, M., and Stockdale, F.E. A positive GATA element and a negative vitamin D receptor-like element control atrial chamber-specific expression of a slow myosin heavy-chain gene during cardiac morphogenesis. 1998. *Mol Cell Biol.* 18(10):6023-34.
3. Bravata, D.M., Sundaram, V., McDonald, K.M., Smith, W.M., Szeto, H., Schleinitz, M.D. and Owens, D.K. Evaluating detection and diagnostic decision support systems for bioterrorism response. 2004. *Emerg Infect Dis.* 10(1):100-8.
4. Schleinitz, M.D., Weiss, J.P. and Owens, D.K. Clopidogrel versus aspirin for secondary prophylaxis of thrombotic events: a cost-effectiveness analysis. 2004. *Am J Med.* 116(12): 797-806.
5. Schleinitz, M.D., Olkin, I. and Heidenreich, P. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. 2004. *Am Heart J.* 148(6): 990-997.
6. Schleinitz, M.D. and Heidenreich, P.A. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. 2005. *Ann Intern Med.* 142(4):251-259.
7. Taveira, T., Wu, W.C., Martin, O.J., Schleinitz, M.D., Friedman, P. and Sharma, S.C. Effectiveness of a pharmacist coordinated interdisciplinary cardiovascular risk reduction clinic for patients with coronary disease or diabetes. 2006. *Prev Cardiol.* (In Press)
8. Schleinitz, M.D. The Cost-Effectiveness of Clopidogrel: A Review by Indication. 2006. *Exp Rev Pharmacoecon Outcome Res.* (In Press)

BOOKS AND BOOK CHAPTERS

Schleinitz, M.D. Drug and Alcohol Abuse, in *Medicine*, 5th Edition. ed. Fishman, M.C. et al., Lipincott, Williams and Wilkins, Philadelphia. 2002.

OTHER NON-PEER REVIEWED PUBLICATIONS

1. Schleinitz, M.D. Cost-effectiveness of antiplatelet therapies. (Letter) 2001. *Arch Int Med.* 161(9):1236.
2. Bravata, D.M., McDonald, K., Owens, D.K., Buckeridge, D., Haberland, C., Rydzak, C., Schleinitz, M., Smith, W.M., Szeto, H., Wilkening, D., Musen, M., Duncan, B.W., Nouri, B., Dangiolo, M.B., Liu, H., Shofer, S., Graham, J., Davies, S. Bioterrorism Preparedness and Response: Use of Information Technologies and Decision Support Systems (Evidence Report/Technology Assessment No. 59 (Prepared by University of California San Francisco-Stanford Evidence-based Practice Center under Contract No. 290-97-0013). AHRQ Publication No. 02-E028. Rockville, MD: Agency for Healthcare Research and Quality. June 2002.
3. Schleinitz, M.D. The effect of clopidogrel on infarct size at one month remains unclear for people with STEMI. Commentary 1. 2005. *Evid Based Cardiovasc Med.* 9(4):280-1.

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. Schleinitz, M.D., Intrator, O., Wu, N. and Mor, V. Getting back home: efficacy of Medicaid bed-hold policies. Submitted 11/05. *JAMA*.
2. Intrator, O., Grabowski, D., Zinn, J., Schleinitz, M.D., Feng, Z., Miller, S.C. and Mor, V. Hospitalization of nursing home residents: The effect of State Medicaid payment and bed-hold policies. Submitted 1/06. *JAMA*.
3. Schleinitz, M.D., DePalo, D., Blume, J. and Stein, M. Association of socio-demographic factors with utilities for breast cancer: implications for disparity. In preparation.
4. Schleinitz, M.D., Blume, J. and Berg, W. Implement or analyze? A value of information analysis of ultrasound for breast cancer screening. In preparation.
5. Schleinitz, M.D. and Heidenreich, P.A. Cilostazol, clopidogrel or ticlopidine for the prevention of stent thrombosis: a cost-effectiveness analysis. In preparation.

ABSTRACTS

1. Schleinitz, M.D., Socks, D.A., Weiss, J.P. and Owens, D.K. Clopidogrel versus aspirin for secondary prophylaxis of thrombotic events: a cost-effectiveness analysis. (Abstract) 2000. *Med Dec Making.* 20(4):484.
2. Schleinitz, M.D., Olkin, I. and Heidenreich, P. Prevention of subacute stent thrombosis: a meta-analysis. (Abstract) 2001. *Med Dec Making.* 21(6):537.
3. Schleinitz, M.D. and Heidenreich, P. Prevention of subacute stent thrombosis: a cost-effectiveness analysis. (Abstract) 2001. *Med Dec Making.* 21(6):519.

4. Schleinitz, M.D. and Heidenreich, P.A. Clopidogrel plus aspirin or aspirin alone for patients with high-risk acute coronary syndrome: a cost-effectiveness analysis. (Abstract) 2003. *J Gen Int Med.* 18(suppl 1):166.
5. Schleinitz, M.D., Blume, J., and Berg, W. Should we study ultrasound for breast cancer screening? A value of information analysis. (Abstract) 2004. *J Gen Int Med.* 19(suppl 1):211.
6. Schleinitz, M.D., Blume, J., and Berg, W. Implement or analyze? A value of information analysis of ultrasound for breast cancer screening. (Abstract) 2005. *Med Dec Making.* 25(1):E16.
7. Schleinitz, M.D., DePalo, D., Blume, J. and Stein, M. Association of socio-demographic factors with utilities for breast cancer: implications for disparity. (Abstract) 2005. *J Gen Int Med.* 20(suppl 1):76.